Keyword Analysis & Research: jcyte
Keyword Research: People who searched jcyte also searched
Search Results related to jcyte on Search Engine
-
Retinitis Pigmentosa | Degenerative Retinal Disorders | jCyte Inc.
https://www.jcyte.com/
WebLearn More. A revolutionary approach – jCell Therapy. jCell is a first-in-class investigational treatment in late-stage clinical development for retinitis pigmentosa (RP), and other inherited retinal and blinding diseases. View ouR Platform. Proprietary platform for multiple ophthalmic indications.
DA: 16 PA: 91 MOZ Rank: 40
-
jCyte Inc. Announces Positive Pre-Phase 3 FDA Type B Meeting …
https://www.jcyte.com/news/press/2024-feb-21/
WebFebruary 21, 2024. NEWPORT BEACH, Calif. – jCyte, Inc., a pioneering biotechnology company dedicated to preserving and restoring vision in patients with retinitis pigmentosa (RP) and other degenerative retinal disorders, is pleased to announce the successful outcome of its pre-phase 3 Type B meeting with the US Food and Drug Administration ...
DA: 59 PA: 21 MOZ Rank: 18
-
jCell Therapy | Retinitis Pigmentosa | Degenerative Retinal ... - jCyte
https://www.jcyte.com/science/
WebjCell Therapy: A novel approach for treating blinding diseases. jCell is a first-in-class allogeneic cell therapy in late-stage clinical development for retinitis pigmentosa. The treatment is a minimally invasive intravitreal injection that can be …
DA: 22 PA: 94 MOZ Rank: 96
-
Latest News and Press Releases | jCyte Inc.
https://www.jcyte.com/news/
WebjCyte Inc. Announces Positive Pre-Phase 3 FDA Type B Meeting and Outlines Plans to Start Pivotal Trial of jCell ® for Retinitis Pigmentosa in The Second Half of 2024. July 6, 2023. jCyte Welcomes New Strategic Advisory Board Members, Experts in Inherited Retinal Diseases. September 20, 2022.
DA: 8 PA: 70 MOZ Rank: 32
-
jCyte, Inc. Identifies Retinitis Pigmentosa Patients Most Likely to
https://www.jcyte.com/news/press/2021-may-03
WebMay 3, 2021 · jCyte, Inc. is a late-stage clinical development biotech company focused on developing its first-in-class regenerative cell therapy, jCell, for RP and other retinal degenerative disorders. The treatment is minimally invasive and given as an intravitreal injection. There are currently no FDA approved therapies for RP.
DA: 86 PA: 91 MOZ Rank: 83
-
jCyte Identifies Key Anatomical Biomarker Predictive of …
https://www.jcyte.com/news/press/2021-nov-15/
WebjCell Therapy. November 15, 2021. NEWPORT BEACH, Calif. – (BUSINESS WIRE) – jCyte, Inc., today announced key findings presented at AAO 2021 which demonstrated that retinitis pigmentosa (RP) patients with a baseline central visual field diameter greater than 20 degrees had a profound response to jCell treatment in its Phase 2b study, the ...
DA: 57 PA: 1 MOZ Rank: 5
-
jCyte, Inc. announces pivotal trial of jCell for RP to start in second
https://www.modernretina.com/view/jcyte-inc-announces-pivotal-trial-of-jcell-for-rp-to-start-in-second-half-of-2024
WebFeb 24, 2024 · The pivotal trial of jCell to treat retinitis pigmentosa (RP) is scheduled to start enrollment during the second half of 2024. According to the company website, jCell is a first-in-class allogeneic cell therapy in late-stage clinical development for treating RP.
DA: 27 PA: 100 MOZ Rank: 1
-
Leadership | Scientific Advisory Board | jCyte Inc.
https://www.jcyte.com/about/
WebOur Mission. Our mission at jCyte is to preserve and restore vision in patients with retinitis pigmentosa and other degenerative retinal disorders. Leadership. John Sholar, JD. Chief Executive Officer. Henry J. Klassen, MD, PhD. Co-Founder and Chairman. Jing Yang, MD, PhD . Co-Founder and Chief Science Officer. Adrian Morris, MS.
DA: 88 PA: 85 MOZ Rank: 97
-
jCyte Identifies Predictive Biomarker for jCell Therapy in
https://eyewire.news/news/jcyte-identifies-predictive-biomarker-for-jcell-therapy-in-largest-phase-3-study-for-retinitis-pigmentosa
Web6 days ago · jCyte announced presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, identifying a predictive biomarker for the upcoming phase 3 study for jCell therapy in retinitis pigmentosa. A detailed analysis by the Cleveland Clinic Cole Eye Institute identified central foveal thickness (CFT), measured by ...
DA: 73 PA: 20 MOZ Rank: 86
-
jCyte Inc. Announces Promising Phase 2b Results of jCell …
https://www.businesswire.com/news/home/20200727005222/en/jCyte-Inc.-Announces-Promising-Phase-2b-Results-of-jCell-Therapy-in-Retinitis-Pigmentosa
WebJul 27, 2020 · NEWPORT BEACH, Calif.-- ( BUSINESS WIRE )-- jCyte Inc ., a biotech company dedicated to preserving and restoring vision in patients with retinitis pigmentosa and other degenerative retinal...
DA: 26 PA: 28 MOZ Rank: 98
